GlassScriptPhysician profile
Alexander Pokov
NPI 1114931532
$3,326.70
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $1,214 · 2021: $787.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $692.63 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $666.52 | 2019-2021 | |
| Allergan, INC. | $336.48 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $274.91 | 2019 | |
| Lilly USA, LLC | $246.86 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $180.09 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.19 | 2019-2020 | |
| Novo Nordisk INC | $128.86 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $108.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.42 | 2019-2020 | |
| Amgen INC. | $74.44 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $72.03 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $69.52 | 2019-2021 | |
| Pfizer INC. | $38.43 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.46 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $20.84 | 2021 | |
| Bausch Health US, LLC | $20.35 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.00 | 2021 | |
| Hikma Pharmaceuticals USA | $17.49 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.24 | 2020 | |
| Glaxosmithkline, LLC. | $16.66 | 2020 | |
| Radius Health, INC. | $14.76 | 2020 | |
| Esperion Therapeutics, INC. | $14.17 | 2021 | |
| Avion Pharmaceuticals | $12.50 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Pokov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.